FOSTER CITY, Calif., May 30, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Karius®, Inc. today announced it has been awarded a contract from the Division of Research, Innovation, and Ventures (DRIVe), under the Biomedical Advanced ...
Chemo-praidict eBC: A deep learning solution for predicting pathological complete response on biopsies of breast cancer patients treated with neoadjuvant chemotherapy. Big data analysis of outcomes in ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results